Skip to main content
Log in

Tigecycline

A Novel Glycylcycline

  • Leading Article
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Antibacterials have been in clinical use for almost 60 years; however, the effectiveness of these valuable agents has been diminished by widespread emergence of bacterial resistance. Tigecycline is the first in a new class of glycylcyclines with activity against a wide range of clinically important pathogens. Tigecycline has demonstrated potent microbiological activity and excellent therapeutic response in animal infection models and in recently reported phase III human clinical trials. It is effective against intra-abdominal and skin and soft tissue infections caused by susceptible or multidrug-resistant staphylococci, enterococci or streptococci as well as most Enterobacteriaceae and anaerobic pathogens. In clinical trials nausea and vomiting were the most common adverse events and were of a magnitude typical of those observed with tetracyclines in general. Additionally, tigecycline has proven to be efficacious in animal models of infection, including pneumonia, endocarditis and peritonitis.

Tigecycline is only available as an intravenous agent and distributes extensively in tissues. Administration of a 100mg loading dose of tigecycline followed by twice-daily doses of 50mg yielded an apparent volume of distribution of 7–10 L/kg. Systemic clearance ranged from 0.2 to 0.3 L/h/kg and its half-life varied from 37 to 67 hours. The pharmacokinetics of tigecycline appear unaffected by sex, age, renal disease or the presence of food. Data from animal studies would suggest that time above the minimum inhibitory concentration is the pharmacodynamic factor that best correlates with bacterial eradication.

The efficacy, safety profile and pharmacodynamic attributes of tigecycline support its continuing clinical development as empirical parenteral treatment of challenging nosocomial and community-acquired infections, including those caused by proven or suspected resistant pathogens.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Table I
Table II
Table III
Table IV
Table V

Similar content being viewed by others

References

  1. Jones RN. Resistance patterns among nosocomial pathogens: trends over the past few years. Chest 2001; 119: 397S–404S

    Article  PubMed  CAS  Google Scholar 

  2. Pihlajamäki M, Kotilainen P, Kaurila T, et al. Macrolide-resistant Streptococcus pneumoniae and use of antimicrobial agents: Finnish Study Group for Antimicrobial Resistance (FiRe-Network). Clin Infect Dis 2001; 33: 483–8

    Article  PubMed  Google Scholar 

  3. Johnson AP, Sheppard CL, Harnett SJ, et al. Emergence of a fluoroquinolone-resistant strain of Streptococcus pneumoniae in England. J Antimicrob Chemother 2003; 52: 953–60

    Article  PubMed  CAS  Google Scholar 

  4. Jones MJ, Blosser-Middleton RS, Critchley IA, et al. In vitro susceptibility of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis: a European multicenter study during 2000–2001. Clin Microbiol Infect 2003; 9: 590–9

    Article  PubMed  CAS  Google Scholar 

  5. Leclercq R, Courvalin P. Resistance to macrolides and related antibiotics in Streptococcus pneumoniae. Antimicrob Agents Chemother 2002; 46(9): 2727–34

    Article  PubMed  CAS  Google Scholar 

  6. Zhanel GG, Palatnick L, Nichol KA, et al. Antimicrobial resistance in respiratory tract Streptococcus pneumoniae isolates: results of the Canadian respiratory organism susceptibility study, 1997 to 2002. Antimicrob Agents Chemother 2003; 47(6): 1867–74

    Article  PubMed  CAS  Google Scholar 

  7. van Ogtrop ML, Andes D, Stamstad TJ, et al. In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various gram-positive and gram-negative bacteria. Antimicrob Agents Chemother 2000; 44(4): 943–9

    Article  PubMed  Google Scholar 

  8. Patel R, Rouse MS, Piper KE, et al. In vitro activity of GAR-936 against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae. Diagn Microbiol Infect Dis 2000; 38: 177–9

    Article  PubMed  CAS  Google Scholar 

  9. Biedenbach DJ, Beach ML, Jones RN. In vitro antimicrobial activity of GAR-936 tested against antibiotic resistant gram-positive blood stream infection isolates and strains producing extended-spectrum β-lactamases. Diagn Microbiol Infect Dis 2000; 40: 173–7

    Article  Google Scholar 

  10. Peterson PJ, Jacobus NV, Weiss WJ, et al. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). Antimicrob Agents Chemother 1999; 43(4): 738–44

    Google Scholar 

  11. Fritsche TR, Kirby JT, Jones RN. In vitro activity of tigecycline (GAR-936) tested against 11,859 recent clinical isolates associated with community-acquired respiratory tract and Gram-positive cutaneous infections. Diagn Microbiol Infect Dis 2004; 49: 201–9

    Article  PubMed  CAS  Google Scholar 

  12. Peterson PJ, Bradford PA, Weiss WJ, et al. In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcusaureusand other resistant gram-positive pathogens. Antimicrob Agents Chemother 2002; 46(8): 2595–601

    Article  Google Scholar 

  13. Rybak MJ, Cheung C, Brown WJ. In vitro evaluation of CB-181963, dapotomycin, arbekacin, tigecycline, quinupristin/dalfopristin, linezolid, gentamicin, doxycycline and rifampin alone and in combination against MRSA, GISA, VRSA and VRE [abstract no. A-1150]. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2003 Sep 14–17; Chicago

  14. Gales AC, Jones RN. Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1203 recent clinical bacterial isolates. Diagn Microbiol Infect Dis 2000; 36: 19–36

    Article  PubMed  CAS  Google Scholar 

  15. Fritsche TR, Strabala P, Sader HS, et al. Activity of tigecycline against tetracycline-resistant Enterobacteriaceae [abstract no. E-2058]. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2004 Oct 30–Nov 2; Washington, DC

  16. Bergeron J, Ammirati M, Danely D, et al. Glycylcyclines bind to the high-affinity tetracycline ribosomal protection. Antimicrob Agents Chemother 1996; 40(9): 2226–8

    PubMed  CAS  Google Scholar 

  17. Bauer G, Berens C, Projan SJ, et al. Comparison of tetracycline and tigecycline binding to ribosomes mapped by dimethyl-sulphate and drug-directed Fe2+ cleavage of 16S rRNA. J Antimicrob Chemother 2004; 53: 592–9

    Article  PubMed  CAS  Google Scholar 

  18. Projan SJ. Preclinical pharmacology of GAR-936, a novel glycylcycline antibacterial agent. Pharmacotherapy 2000; 20 (9 Pt 2): 219S–23S

    Article  PubMed  CAS  Google Scholar 

  19. Pioletti M, Schluenzen F, Harms J, et al. Crystal structures of complexes of the small ribosomal subunit with tetracycline, edeine and IF3. EMBO J 2001; 20(8): 1829–39

    Article  PubMed  CAS  Google Scholar 

  20. Someya Y, Yamaguchi A, Sawai T. A novel glycylcycline, 9-(N,N-dimethylglycylamido)-6-demethyl-6-deoxytetracycline, is neither transported nor recognized by the transposon Tn10-encoded metal-tetracycline/H+ antiporter. Antimicrob Agents Chemother 1995; 39(1): 247–9

    Article  PubMed  CAS  Google Scholar 

  21. Sum PE, Sum FW, Projan SJ. Recent developments in tetracycline antibiotics. Curr Pharm Des 1998; 4: 119–32

    PubMed  CAS  Google Scholar 

  22. Chopra I, Roberts M. Tetracycline antibiotics: mode of action, applications, molecular biology and epidemiology of bacterial resistance. Microbiol Mol Biol Rev 2001; 62(2): 232–60

    Article  Google Scholar 

  23. Rasmussen BA, Gluzman Y, Tally FP. Inhibition of protein synthesis occurring on tetracycline-resistant, TetM-protected ribosomes by a novel class of tetracyclines, the glycylglycines. Antimicrob Agents Chemother 1994; 38: 1658–60

    Article  PubMed  CAS  Google Scholar 

  24. Jones RN, Deshpande LM, Mutnick AH, et al. In vitro evaluation of BAL9141 a novel parenteral cephalosporin active against oxacillin-resistant staphylococci. J Antimicrob Chemother 2002; 50: 915–32

    Article  PubMed  CAS  Google Scholar 

  25. Oteo J, Baquero F, Vindel A, et al. Antibiotic resistance in 3113 blood isolates of Staphylococcusaureusin 40 Spanish hospitals participating in the European Antimicrobial Resistance Surveillance System (2000–2002): Spanish members of the European Antimicrobial Resistance Surveillance System. J Antimicrob Chemother 2004; 53: 1033–8

    Article  PubMed  CAS  Google Scholar 

  26. Fey PD, Saïd-Salim B, Rupp ME, et al. Comparative molecular analysis of community- or hospital-acquired methicillin-resistant Staphylococcusaureus. Antimicrob Agents Chemother 2003; 47(1): 196–203

    Article  PubMed  CAS  Google Scholar 

  27. Smith Moland E, Black JA, Ourada J, et al. Occurrence of newer β-lactamases in Klebsiellapneumomiaeisolates from 24 US hospitals. Antimicrob Agents Chemother 2002; 46(12): 3837–42

    Article  Google Scholar 

  28. Visalli MA, Murphy E, Projan SJ, et al. AcrAB multidrug efflux pump is associated with reduced levels of susceptibility to tigecycline (GAR-936) in Proteusmirabilis. Antimicrob Agents Chemother 2003; 47(2): 665–9

    Article  PubMed  CAS  Google Scholar 

  29. National Committee for Clinical Laboratory Standards (NC-CLS). Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: approved standard. 6th ed. Document M7-A6. Wayne (PA): NCCLS, 2003

    Google Scholar 

  30. National Committee for Clinical Laboratory Standards (NCCLS). Performance standards for antimicrobial susceptibility testing, 14th information supplement. Document M100-S14. Wayne (PA): NCCLS, 2004

    Google Scholar 

  31. Bouchillon S, Stevens T, Johnson B, et al. Tigecycline Evaluation Surveillance Trial (T.E.S.T.): global in vitro antibacterial activity against gram-positive and gram-negative pathogens [abstract no. P809]. 15th European Congress of Clinical Microbiology and Infectious Diseases; 2005 Apr 2–5; Copenhagen

  32. Jones RN, Sader HS, Stilwell MG, et al. Tigecycline activity tested against 22,950 bloodstream infection isolates worldwide [abstract no. P820]. 15th European Congress of Clinical Microbiology and Infectious Diseases; 2005 Apr 2–5; Copenhagen

  33. Jones RN, Stilwell MG, Sader HS, et al. In vitro efficacy of tigecycline tested against community-acquired respiratory tract infection and nosocomial pneumonia pathogens [abstract no. P1208]. 15th European Congress of Clinical Microbiology and Infectious Diseases; 2005 Apr 2–5; Copenhagen

  34. Fritsche TR, Sader HS, Jones RN. Activity of tigecycline tested against an international collection (1999–2003) of resistant bacterial pathogens [abstract no. P1209]. 15th European Congress of Clinical Microbiology and Infectious Diseases; 2005 Apr 2–5; Copenhagen

  35. Sader HS, Fritsche TR, Jones RN. Antimicrobial activity of tigecycline tested against bacterial pathogens from intensive care units [abstract no. P818]. 15th European Congress of Clinical Microbiology and Infectious Diseases; 2005 Apr 2–5; Copenhagen

  36. Fritsche TR, Sader HS, Stilwell MG, et al. Potency and spectrum of tigecycline tested against an international collection (1999–2003) of bacterial infections producing skin and soft tissue infections [abstract no. P819]. 15th European Congress of Clinical Microbiology and Infectious Diseases; 2005 Apr 2–5; Copenhagen

  37. Mikels SM, Brown AS, Breden L, et al. In vivo activities of GAR-936 (GAR), gentamicin (GEN), piperacillin (PIP) alone and in combination in a murine model of Pseudomonasaeruginosa pneumonia [abstract no. 414]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999 Sep 26–29; San Francisco

  38. Milatovic D, Verhoef SJ, Fluit AC. Activities of the glycylcycline tigecycline (GAR-936) against 1,924 recent European clinical bacterial isolates. Antimicrob Agents Chemother 2003; 47(1): 400–4

    Article  PubMed  CAS  Google Scholar 

  39. Cuevas O, Cercenado E, Guinea JV, et al., and the Staphylococcus Study Group. In vitro activities of linezolid, moxifloxacin, quinupristin/dalfopristin and tigecycline against recent clinical isolates of Staphylococcusspp. in Spain [abstract]. 14th European Congress of Clinical Microbiology and Infectious Diseases; 2004 May 1–4; Prague

  40. Betriu C, Rodríguez-Avial I, Sánchez BA, et al. In vitro activities of tigecycline (GAR-936) against recently isolated clinical bacteria in Spain: Spanish Group of Tigecycline. Antimicrob Agents Chemother 2002; 46(3): 892–5

    Article  PubMed  CAS  Google Scholar 

  41. Cercenado E, Marin M, Martinez-Alarcón, et al. In vitro activities of new antimicrobials against different Nocardiaspecies [abstract no. E-2062]. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2004 Oct 30–Nov 2; Washington, DC

  42. Jacobus NV, McDermott LA, Ruthazer R, et al. In vitro activities of tigecycline against the Bacteroidesfragilisgroup. Antimicrob Agents Chemother 2004; 48(3): 1034–6

    Article  PubMed  CAS  Google Scholar 

  43. Betriu C, Culebras E, Gomez M, et al. In vitro activity of tigecycline against Bacteroidesspecies [abstract no. E-2057]. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2004 Oct 30–Nov 2; Washington, DC

  44. Zhanel GG, Homenuik K, Nichol K, et al. The glycylcyclines: a comparative review with the tetracyclines. Drugs 2004; 64(1): 63–88

    Article  PubMed  CAS  Google Scholar 

  45. Muralidharan G, Micalizzi M, Speth J, et al. Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. Antimicrob Agents Chemother 2005; 49(1): 220–9

    Article  PubMed  CAS  Google Scholar 

  46. Zimmerman JJ, Harper D, Matschke K, et al. Tigecycline and digoxin co-administered to healthy men [abstract no. A-460]. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2004 Oct 30–Nov 2; Washington, DC

  47. Muralidharan G, Getsy J, Mayer P, et al. Pharmacokinetics (PK), safety and tolerability of GAR-936, a novel glycylcycline antibiotic, in healthy subjects [abstract no. 416]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999 Sep 26–29; San Francisco

  48. Muralidharan G, Mojavarian P, Micalizzi M, et al. The effects of age and gender on the pharmacokinetics, safety and tolerability of GAR-936, a novel glycylcycline antibiotic, in healthy subjects [abstract no. 502]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 17–20; Toronto

  49. Troy SM, Muralidharan G, Micalizzi M, et al. The effects of renal disease on the pharmacokinetics of tigecycline (GAR-936) [abstract no. A-22]. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2003 Sep 14–17; Chicago

  50. Meagher AK, Cirincione BB, Piedmonte MR, et al. Pharmacokinetics (PK) of tigecycline (TG) in healthy adult volunteers and in subjects with renal impairment [abstract]. 14th European Congress of Clinical Microbiology and Infectious Diseases; 2004 May 1–4; Prague

  51. Postier RG, Green SL, Klein SR, et al. Results of a multicenter, randomized, open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin-structure infections in hospitalized patients. Clin Ther 2004; 26(5): 704–14

    Article  PubMed  CAS  Google Scholar 

  52. Owen JS, Darling IM, Troy SM, et al. Noncompartmental pharmacokinetics of tigecycline in patients with complicated skin and skin structure infections [abstract no. A-11]. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2004 Oct 30–Nov 2; Washington, DC

  53. Murray J, Wilson S, Klein S, et al. The clinical response to tigecycline in the treatment of complicated intra-abdominal infections in hospitalized patients, a phase 2 clinical trial [abstract no. L-739]. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2003 Sep 14–17; Chicago

  54. Tombs NI. Tissue distribution of GAR-936, a broad spectrum antibiotic, in male rats [abstract no. 413]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999 Sep 26–29; San Francisco

  55. Conte JE, Golden JA, Kelly MG, et al. Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline [abstract no. 322]. 42nd Meeting of Infectious Diseases Society of America; 2004 Sep 30–Oct 3; Boston

  56. Lefort A, Lafaurie M, Massias L, et al. Activity and diffusion of tigecycline (GAR-936) in experimental enterococcal endocarditis. Antimicrob Agents Chemother 2003; 47(1): 216–22

    Article  PubMed  CAS  Google Scholar 

  57. Edelstein PH, Weiss W, Edelstein M. Tigecycline (GAR-936) activity versus Legionellain vitro and in a cell and animal model of Legionnaires disease [abstract no. E-1139]. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2002 Sep 27–30; San Diego

  58. Mikels SM, Lenoy E, Allen W, et al. Therapeutic efficacy of GAR-936 (GAR), a novel glycylcycline, in murine infections [abstract]. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1998 Sep 24–27; San Diego

  59. Dean CR, Visalli MA, Projan SJ, et al. Efflux-mediated resistance to tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1. Antimicrob Agents Chemother 2003; 47(3): 972–8

    Article  PubMed  CAS  Google Scholar 

  60. Lefort A, Lefaurie M, Saleh-Mghir A, et al. Activity and diffusion of GAR-936 (GAR) in experimental enterococcal endocarditis [abstract no. 415]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999 Sep 26–29; San Francisco

  61. Murphy TM, Deitz JM, Petersen PJ, et al. Therapeutic efficacy of GAR-936, a novel glycylcycline, in a rat model of experimental; endocarditis. Antimicrob Agents Chemother 2000; 44(11): 3022–7

    Article  PubMed  CAS  Google Scholar 

  62. Nannini EC, Pai SR, Singhh KV, et al. Activity of tigecycline (GAR-936), a novel glycylcycline, against enterococci in the mouse peritonitis model. Antimicrob Agents Chemother 2003; 47(2): 529–32

    Article  PubMed  CAS  Google Scholar 

  63. Dartois N, on behalf of the Tigecycline 305 cSSSI Study Group. Results of a phase 3, double-blind, safety and efficacy study comparing tigecycline with vancomycin/aztreonam to treat complicated skin and skin structure infections [abstract no. L-986]. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2004 Oct 30–Nov 2; Washington, DC

  64. Dartois N, Gioud-Paquet M, Ellis-Grosse EJ, et al. Tigecycline versus imipenem/cilastatin for treatment of complicated intra-abdominal infections [abstract no. L-992c]. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2004 Oct 30–Nov 2; Washington, DC

  65. Johnson B, Stevens T, Bouchillon S, et al. In vitro study of tigecycline (GAR-936) against 776 clinical isolates of non-Enterobacteriaceae from hospitals across Europe [abstract no. E-1533]. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2003 Sep 14–17; Chicago

  66. Reynolds R, Potz N, BSAC Working Party on Bacteraemia Resistance Surveillance. Activity of tigecycline against 2206 recent bacteremia isolates in the UK and Eire [abstract no. E-1532]. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2003 Sep 14–17; Chicago

  67. Reynolds R, Hope R, on behalf of the BSAC Working Party on Bacteraemia Resistance Surveillance. Antimicrobial susceptibility among invasive gram-negative bacteria in the UK and Ireland: the BSAC Bacteraemia Resistance Surveillance Programme 2003 [abstract no. P1793]. 15th European Congress of Clinical Microbiology and Infectious Diseases; 2005 Apr 2–5; Copenhagen

  68. Reynolds R, Coleman M, on behalf of the BSAC Working Party on Bacteraemia Resistance Surveillance. Antimicrobial susceptibility among invasive gram-positive bacteria in the UK and Ireland: the BSAC Bacteraemia Resistance Surveillance Programme 2003 [abstract no. R1999]. 15th European Congress of Clinical Microbiology and Infectious Diseases; 2005 Apr 2–5; Copenhagen

  69. Passarell JA, Meagher AK, Liolios K, et al. Pharmacokinetic/pharmacodynamic model for the tolerability of tigecycline in healthy volunteers [abstract no. P894]. 15th European Congress of Clinical Microbiology and Infectious Diseases; 2005 Apr 2–5; Copenhagen

Download references

Acknowledgements

The authors wish to thank Annie Jones for scientific and technical support. Drs Rubinstein and Vaughan have received funding from Wyeth. Ethan Rubinstein has received research grants from: Aventis, Bayer, Pfizer, Theravance, ImmunoGen and Daiichi; and has given lectures for fee for Aventis, GSK, Pfizer and Daiichi. He has been or is consultant for Johnson & Johnson, AstraZeneca, Bayer, Theravance, ImmunoGen, Teva, GSK, Pfizer, Aventis, Wyeth, Cubist and BMS.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Ethan Rubinstein.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rubinstein, E., Vaughan, D. Tigecycline. Drugs 65, 1317–1336 (2005). https://doi.org/10.2165/00003495-200565100-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200565100-00002

Keywords

Navigation